Yidu Bencao Pharmaceutical

Beijing Yidu Bencao Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Beijing, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets metabolic diseases, such as type 2 diabetes, and various oncology indications. Its lead candidate, YB-211, is a potent and selective G protein-coupled receptor 40 (GPR40) agonist currently in Phase 2 clinical development for the treatment of type 2 diabetes. Yidu Bencao utilizes its proprietary drug discovery platform to advance a pipeline of Class 1 new drugs designed to provide superior clinical benefits. The company is committed to addressing significant unmet medical needs through rigorous scientific research and strategic clinical development.